5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma: A randomized trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 19, Issue 5, 1996, Pages 517-521

  Tsavaris, N B ^a   Tentas, K ^a   Kosmidis, P ^a   Mylonakis, N ^a   Sakelaropoulos, N ^a   Kosmas, C ^a   Lisaios, B ^a   Soumilas, A ^a   Mandrekois, D ^a   Tsetis, A ^a   Klonaris, C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; MITOMYCIN C;

ADULT; AGED; ARTICLE; BOLUS INJECTION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; STOMACH CARCINOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 10144261893     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199610000-00018     Document Type: Article

References (14)

1. MacDonald JS, Wooley PV, Smythe T, Ueneo W, Hoth D, Schein PS. 5-fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in the treatment of advanced gastric cancer. Cancer 1979;44:42-7.
2. Bertino JR, Sawicki WL, Linquist CA. Schedule-dependent anti-tumor effects of methotrexate and 5-fluorouracil. Cancer Res 1977;37:327.
3. Klein H, Wickramanayake PD, Dieterle F, Mohr R, Oerkermann H, Gross R. High-dose MTX/5FU and adriamycin for gastric cancer. Semin Oncol 1983;10:29-31.
4. The Gastrointestinal Tumor Study Group. Triazinate and platinum efficacy in combination with 5-fluorouracil and doxoroubicin results of a three-arm randomized trial in metastatic gastric cancer. J Natl Cancer Inst 1988;80:1011-5.
5. Findlay M, Cunningham D. Chemotherapy of carcinoma of the stomach. Cancer Treat Rev 1993;19:29-44.
6. Preusser P, Wilke H, Achterrath W, et al. Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989;7:1310-7.
7. Wilke H, Preusser P, Fink U, et al. New developments in the treatment of gastric carcinoma. Semin Oncol 1990;17:61-70.
8. Arbuck SG, Silk V, Douglass O. Nava HN, Rustum YM, Milliron S. A phase II trial of 5-fluorouracil, doxoroubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. Cancer 1990;65:2442-5.
9. Zaniboni A. Simoncini E, Marpicati P, et al. Mitomycin C, adriamycin, 5-fluorouracil and leucovorin in the treatment of advanced gastric cancer: a phase II study. Tumori 1991;77:160-3.
10. Miller A. Hoogstraten B. Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-17.
11. Gralla R. Approaches to management of emesis. Clinician 1988;6:26.
12. Kaplan EL, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-81.
13. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
14. Hryniuk WM. Average relative dose intensity and the impact on design on clinical trials. Semin Oncol 1987;14:65-74.